Yanke xuebao, 2015-06, Vol.30 (2), p.63-66
2015
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Intravitreal Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion in Chinese Patients
- Ist Teil von
- Yanke xuebao, 2015-06, Vol.30 (2), p.63-66
- Ort / Verlag
- Department of Healthcare Administration and Department of Nursing , Oriental Institute of Technology , New Taipei City , Taiwan , China
- Erscheinungsjahr
- 2015
- Quelle
- Alma/SFX Local Collection
- Beschreibungen/Notizen
- Purpose： To investigate the short-term efficacy and safety of intravitreal aflibercept in a case series of patients from Tai- wan, China, with macular edema secondary to branch retinal vein occlusion （BRVO）. Methods： A total of 32 patients with macular edema associated with BRVO, without prior macular laser or other inter- vention, were enrolled consecutively from September 2013 to February 2015. The cases received single 2 mg injections of intravitreal aflibercept. Primary outcome measures included changes in central foveal thickness （CFT; 1 mm increments by spectral-domain optic coherence tomography） and best corrected visual acuity （BCVA）, determined at 1, 2, and 3 months after the injection. Complications after injections were recorded. The changes in CFT and BCVA were compared with Wilcoxon sign-rank tests. Results： The CFT was significantly reduced and the BCVA was significantly improved at 1, 2, and 3 months after injec- tion （all P 〈 0.05）. Tomography findings revealed no recur- rence within 3 months. No systemic thrornboembolic events, elevated intraocular pressure, retinal detachment, or infectious endophthalmitis occurred following injection. Conclusion： Single intravitreal aflibercept may be useful in treating macular edema associated with BRVO within 3 months. No adverse systemic or ocular effects were found in this case series. （Eye Science 2015; 30：63-66）